Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (not Palvela Therapeutics, Inc.) on April 18, 2024. The filing announces a material modification to the rights of security holders involving a reverse stock split of the Company's common stock.
Key Financial Metrics and Capitalization
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capitalization changes resulting from the reverse stock split.
- Reverse Stock Split Ratio: 1-for-80.
- Pre-Split Outstanding Shares: 98,935,025 (as of April 11, 2024).
- Post-Split Outstanding Shares: Approximately 1,236,688 (subject to rounding adjustments).
- Pre-Split Authorized Shares: 300,000,000.
- Post-Split Authorized Shares: 3,750,000.
- Trading Symbol: PIRS (unchanged).
- New CUSIP Number: 720795202.
Material Changes Versus Prior Period
The primary material change is the reduction in the number of outstanding shares and the corresponding increase in the per-share price to regain compliance with Nasdaq listing standards.
- Compliance Driver: The split is intended to raise the per-share bid price above $1.00 to comply with Nasdaq Listing Rule 5550(a)(2).
- Effective Date: The split becomes effective at or about 5:00 pm New York time on April 22, 2024.
- Trading Resumption: Trading on a split-adjusted basis begins at the market open on April 23, 2024.
- Ownership Impact: Relative ownership interest and proportional voting power remain virtually unchanged, except for minor adjustments due to rounding fractional shares up to whole shares.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the effectiveness of the Certificate of Change and the ability to regain Nasdaq compliance.
- Compliance Timeline: The Company will regain compliance once the stock trades at or above $1.00 for a minimum of 10 consecutive trading days.
- Fractional Shares: No cash will be paid for fractional shares; they will be rounded up to one whole share.
- Derivatives Adjustment: Outstanding options and warrants will be adjusted by dividing the share count by 80 and multiplying the exercise price by 80.
- Risks: The Company notes that actual results may differ from forward-looking statements due to risks described in its Form 10-K and 10-Q, including the risk of failing to maintain the Nasdaq listing.
Important Facts for Investor Verification
- Verify the post-split share count in brokerage accounts on or after April 23, 2024.
- Confirm the new CUSIP number (720795202) for record-keeping purposes.
- Monitor the stock price to ensure it sustains the $1.00 threshold for 10 consecutive trading days to secure Nasdaq compliance.
- Review the adjustment of any held options or warrants to ensure exercise prices and share quantities were correctly updated.
- Note that stockholders holding paper certificates must mail them to Computershare to receive new shares.